Repositioning Candidate Details
| Candidate ID: | R0914 |
| Source ID: | DB06011 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | AMG-222 |
| Synonyms: | -- |
| Molecular Formula: | C32H39N9O3 |
| SMILES: | [H][C@](C)(CC1(C2=NNN=N2)C2=CC=C(C=C2CCC2=CC(=CC=C12)C(=O)N(C)C)C(=O)N(C)C)NCC(=O)N1CCC[C@@]1([H])C#N |
| Structure: |
|
| DrugBank Description: | -- |
| CAS Number: | 913978-37-7 |
| Molecular Weight: | 597.724 |
| DrugBank Indication: | Investigated for use/treatment in diabetes mellitus type 2. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | AMG-222 is an orally active, small molecule inhibitor of Dipeptidyl Peptidase IV (DPP-IV). DPP-IV inactivates glucagon-like peptide-1 (GLP-1), an important mediator of blood glucose levels following meals. DPP-IV inhibitors have been clinically shown to provide long term improvement of glucose control without the risk of hypoglycemia, and to improve the function of pancreatic beta cells, the cells responsible for the production of insulin. DPP-IV inhibitors represent a novel approach to the treatment of type II diabetes. |
| Targets: | Dipeptidyl peptidase 4 |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |